Polysaccharide-Protein Conjugates: A New Generation of Vaccines

Our main interest has been toward preventing meningitis and other systemic infections caused by Haemophilus influenzae type b (Hib). The advent of Hib conjugates licensed for universal immunization of infants, administered concurrently with diphtheria and tetanus toxoids and pertussis vaccine (DTP),...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Infectious Diseases 1990-05, Vol.161 (5), p.821-832
Main Authors: Robbins, John B., Schneerson, Rachel
Format: Article
Language:English
Subjects:
Animals
Antibodies
Antigens
Applied microbiology
Bacteremia
Bacterial Capsules
Bacterial Vaccines
Biological and medical sciences
Children
Fundamental and applied biological sciences. Psychology
Haemophilus Infections - prevention & control
Haemophilus influenzae
Haemophilus influenzae - immunology
Haemophilus Vaccines
Humans
IDSA Meeting Presentations
Immunity
Infections
Intestinal Diseases - prevention & control
lipopolysaccharides
meningitis
Meningitis - prevention & control
Microbiology
Pathogens
Polysaccharides
Polysaccharides, Bacterial
proteins
Salmonella - immunology
Sepsis - prevention & control
Shigella - immunology
Streptococcus pneumoniae
Tetanus Toxoid
Typhoid Fever - prevention & control
Typhoid-Paratyphoid Vaccines
Vaccination
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Synthetic
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Our main interest has been toward preventing meningitis and other systemic infections caused by Haemophilus influenzae type b (Hib). The advent of Hib conjugates licensed for universal immunization of infants, administered concurrently with diphtheria and tetanus toxoids and pertussis vaccine (DTP), is imminent. In addition to reviewing our contributions and those of our colleagues with these new Hib vaccines, we will illustrate how the development of polysaccharide-protein conjugates may provide opportunities for studying the pathogenesis of other bacterial diseases and ultimately for preventing them through new vaccines. Both capsular polysaccharides and lipopolysaccharides (LPS) have immunologic properties and LPS also have pharmacologic activities that limit their use as vaccines. The development of synthetic schemes for preparing clinically acceptable polysaccharide-protein conjugates allows us to skirt these limitations.
ISSN:0022-1899
1537-6591
1537-6613
DOI:10.1093/infdis/161.5.821